Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

A is CH or nitrogen;

B is $-CH_2-$, -CHF-, $-CF_2-$, NR_4 or O, with the proviso that when A is N, B is $-CH_2-$, -CHF- or $-CF_2-$;

G is oxygen,

R_1 is hydrogen or C_{1-6} alkyl;

R_2 is C_{1-8} alkyl, $-CH_2$-aryl, CH_2-heterocycle,$-CH_2$-substituted C_5 cycloalkyl, or a $-CH_2$-substituted hetero cycle, each of which may be optionally substituted with one or more of halo, hydroxyl,

C_{1-6} alkyl, C_{1-6} haloalky, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

R_3 is hydrogen; cyclobutyl, cyclopropyl, methyl, ethyl, isopropyl, butyl, sec-butyl;

R_5 is a 5-membered unsaturated heterocyclic ring having one of the following structures:



R_6 is methyl, aralkyl, arylamino, aralkyl substituted by one or more halo and having a methylene group linking the aryl to the unsaturated 5-membered ring, aralkyl substituted by one or more halo and having an ethylene group linking the aryl to the unsaturated 5-membered ring;or

R_5 may also be C_2-C_4-aralkyl, -CH_2-O-R_7 where R_7 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_2-C_4 aralkyl which groups may be optionally substituted with fluoro or hydroxy; and

R_8 is hydrogen phenyl or halo-substituted phenyl;

with the proviso that when either R_3 or R_8 is not hydrogen, the other is hydrogen.

2. (cancel)

3. (previously presented) A compound according to claim 1, wherein

R_1 is H;

R_2 is -CH_2-aryl optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkeny1, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

R_3 is hydrogen or cyclobutyl;

R_5 is one of the following 5-membered unsaturated heterocyclic ring structures:



;

R_6 is phenyl, phenylamino substituted by one or more halo, phenylmethyl substituted by one or more halo, or phenethyl substituted by one or more halo; and

R_8 is hydrogen or a fluoro-substituted phenyl.

4. (previously presented) A compound according to claim 3, wherein

R_2 is $-CH_2-C_6H_5$ or $-CH_2$-heterocyclic aryl each of which may be optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

R_3 is H;

R_5 is one of the following 5-membered unsaturated heterocyclic ring structures:



;

R_6 is a meta chloro-substituted phenylamino, a meta chloro-substituted phenylmethy or a meta chloro-substituted phenethyl; and

R_8 is 3,5-difluorophenyl.

5. (previously presented) A compound according to claim 1, wherein

A is CH;

B is $-CH_2-$;

G is oxygen;

R_1 is hydrogen;

R_2 is C_{1-8} alkyl or $-CH_2$-aryl (optionally substituted by one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkyny);

R_3 is cyclobutyl or H, and

R_5 is one of the following 5 -membered unsaturated heterocyclic ring structures:



;

6. (previously presented) A compound according to claim 1, in which A is CH;

B is O;

G is oxygen;

R_1 is hydrogen;

R_2 is C_{1-8} alkyl, $-CH_2$-aryl (optionally substituted by one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

R_3 is cyclobutyl or H; and

R_5 is $-CH_2-O-CH_3$, $-CH_2-O-CH_2-CH_2-C_6H_5$ or one of the following 5-membered unsaturated heterocyclic ring structures:



;

7. (previously presented) A compound according to claim 1, wherein .

A is CH;

B is NH;

G is oxygen;

R_1 is hydrogen;

R_2 is C_{1-8} alkyl, $-CH_2$-aryl, a $-CH_2$-heterocyclic group or a $-CH_2$-substituted C_5 cycloalkyl (optionally substituted by one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

R_3 is cyclobutyl or H; and

R_5 is $-CH_2-O-CH_3$, $-CH_2-O-CH_2-CH_2-C_6H_5$ or one of the following 5-membered unsaturated heterocyclic ring structures:



;

8. (previously presented) A compound according to claim 1, wherein

A is N;

B is $-CH_2-$;

G is oxygen;

R_1 is hydrogen;

R_2 is C_{1-8} alkyl, $-CH_2$-aryl, a $-CH_2$-heterocyclic group or a $-CH_2$-substituted C_5 cycloalkyl (optionally substituted one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

R_3 is cyclobutyl or H;

R_5 is one of the following 5-membered unsaturated heterocyclic ring structures:



;

and

R_8 is H or phenyl (optionally substituted with halo).

9. (previously presented) A compound according to claim 1, wherein

A is N;

B is $-CH_2-$;

G is oxygen;

R_1 is hydrogen;

R_2 is C_{1-8} alkyl $-CH_2$-aryl, a $-CH_2$-heterocyclic group or a $-CH_2$-substituted C_5 cycloalkyl (optionally substituted by one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalky, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

R_3 is cyclobutyl or H; and

R_5 is $-CH_2-O-CH_3$.

10. (previously presented) A compound according to claim 1,wherein

A is N;

B is $-CH_2-$;

R_1 is hydrogen;

R_3 is hydrogen or cyclobutyl;

R_5 is one of the following 5-membered unsaturated heterocyclic ring structures:



;

and R_8 is phenyl,3,5-difluorophenyl or H.

11. (original) A compound according to claim 1, having the formula:



12. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 .

13. (cancel)

14. (currently amended) A method for the manufacture~~of manufacturing~~ of a pharmaceutical for the modification of an acetylcholine or a muscarinic receptor comprising the step of placing the compound of claim 1 into a pharmaceutical composition in a unit dosage form.

15. (currently amended) The method of claim 14, wherein the pharmaceutical is for the treatment of~~is for~~ Alzheimer's disease.

16. (currently amended) A method of modifying a muscarinic acetylcholine receptor or an acetylcholine receptor comprising the administration of a therapeutically effective amount of a compound as claimed in claim 1 to a subject in need thereof.

17. (currently amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

A is CH or nitrogen;

B is $-CH_2-$, -CHF-, $-CF_2-$, NR_4 or O, with the proviso that when A is N, B is $-CH_2-$, -CHF- or $-CF_2-$;

G is oxygen or =N-CN,

R_1 is hydrogen or C_{1-6} alkyl;

R_2 is hydrogen; C_{1-10} alkyl optionally substituted with C_{1-6} alkoxy or halogen; aralkyl, a $-CH_2$-heterocycle or a $-CH_2-C_5$ cycloalkyl ring each of which may be optionally substituted with one or more of halo, hydroxyl, C_{1-6} alkyl, C_{1-6} haloalky, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

R_3 is a cyclic alkyl radical containing from 3-6 carbon atoms or a C_1-C_6 alkyl;

R4 is hydrogen or lower alkyl;

R5 is a 5-membered unsaturated heterocyclic ring optionally substituted by a group selected from~~and~~

~~R6 is~~ lower alkyl; ~~hydrogen;~~ arylamino optionally substituted with one or more of halo, hydroxy, C1-6 alkyl, Cl-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl; aralkyl optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy,
C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or
C_{2-6} haloalkynyl; or a group of formula:



wherein n is an integer in the range from 1 to 4 and HET is a heterocyclic group optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

or R_5 may also be C_2-C_4-aralkyl, -CH_2-O-R_7 where R_7 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_2-C_4 aralkyl which groups may be optionally substituted with fluoro or hydroxy; and

R_8 is hydrogen or aryl (optionally substituted with one or more of halo, hydroxyl, C_{1-6} alkyl, C_{1-6} haloalky, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

with the proviso that when either R3 or R8 is not hydrogen, the other is hydrogen.